Unichem Pharma announces new CEO for its parent

By ROI-NJ Staff
Hasbrouck Heights | Jun 22, 2018 at 12:30 pm

Unichem Pharmaceuticals USA Inc., a Hasbrouck Heights-based specialty generic pharmaceutical company, announced Thursday it has a new CEO for its parent company.

Scott Delaney has joined the company as its CEO and president, North America, for Unichem Laboratories Ltd., based in India. He has also been named a member of the company’s board of directors.

Delaney has more than 24 years of experience in brand and generic pharmaceutical management. Prior to Unichem, he worked at with Eli Lilly and Co., Johnson and Johnson, HEB Grocery Co., Teva Pharmaceuticals, URL Pharma, Cadista Pharmaceuticals, and Edenbridge Pharmaceuticals.  Most recently, he was president  of Heritage Pharmaceuticals Inc., a division of Emcure Pharmaceuticals.

“I am honored to accept the role of president and chief executive officer – North America for Unichem at this exciting time for the company.  Dr. Mody and the entire Unichem team, have been extremely welcoming to me and my family.  They have built a tremendous organization and are very well positioned for the future in the pharmaceutical industry.  I look forward to continue to build on this success while helping to identify new and exciting opportunities that will create additional long-term value for Unichem Laboratories,” Delaney said.

“With our committed global focus, built on our strength and capabilities, we are confident that with Scott’s leadership and dynamism we will reach greater heights,” Mody said.

ROI-NJ Staff | editorial@roi-nj.com | @ROINJNews